Please use this identifier to cite or link to this item: https://doi.org/10.1016/j.antiviral.2012.07.008
DC FieldValue
dc.titleDose- and schedule-dependent protective efficacy of celgosivir in a lethal mouse model for dengue virus infection informs dosing regimen for a proof of concept clinical trial
dc.contributor.authorWatanabe, S.
dc.contributor.authorRathore, A.P.S.
dc.contributor.authorSung, C.
dc.contributor.authorLu, F.
dc.contributor.authorKhoo, Y.M.
dc.contributor.authorConnolly, J.
dc.contributor.authorLow, J.
dc.contributor.authorOoi, E.E.
dc.contributor.authorLee, H.S.
dc.contributor.authorVasudevan, S.G.
dc.date.accessioned2014-11-26T08:27:50Z
dc.date.available2014-11-26T08:27:50Z
dc.date.issued2012-10
dc.identifier.citationWatanabe, S., Rathore, A.P.S., Sung, C., Lu, F., Khoo, Y.M., Connolly, J., Low, J., Ooi, E.E., Lee, H.S., Vasudevan, S.G. (2012-10). Dose- and schedule-dependent protective efficacy of celgosivir in a lethal mouse model for dengue virus infection informs dosing regimen for a proof of concept clinical trial. Antiviral Research 96 (1) : 32-35. ScholarBank@NUS Repository. https://doi.org/10.1016/j.antiviral.2012.07.008
dc.identifier.issn01663542
dc.identifier.urihttp://scholarbank.nus.edu.sg/handle/10635/110037
dc.description.abstractCelgosivir (6-O-butanoyl castanospermine), a pro-drug of the naturally occurring castanospermine, is an inhibitor of α-glucosidase I and II that is found to be a potent inhibitor of several enveloped viruses including all four serotypes of dengue virus. We showed previously that the compound fully protected AG129 mice from lethal infection with a mouse adapted dengue virus at a dose of 50. mg/kg twice daily (BID) for 5. days and was effective even after 48. h delayed treatment. Here we show that the protection by celgosivir is dose- and schedule-dependent and that a twice-a-day regimen of 50, 25 or 10. mg/kg is more protective than a single daily dose of 100. mg/kg. Treatment with 50. mg/kg BID castanospermine had comparable efficacy as 25. mg/kg BID celgosivir, suggesting that celgosivir is approximately twice as potent as castanospermine with respect to in vivo antiviral efficacy. Pharmacokinetics (PK) studies of celgosivir in mice showed that it rapidly metabolized to castanospermine. Simulation of the PK data with the survival data for the various doses of celgosivir tested suggests that the steady-state minimum concentration is a critical parameter to note in choosing dose and schedule. These results influenced the selection of the dose regimen for a proof-of-concept clinical trial of celgosivir as a treatment against dengue fever. © 2012 Elsevier B.V.
dc.description.urihttp://libproxy1.nus.edu.sg/login?url=http://dx.doi.org/10.1016/j.antiviral.2012.07.008
dc.sourceScopus
dc.subjectAG129 lethal infection mouse model
dc.subjectAntiviral
dc.subjectDengue virus
dc.subjectPharmacokinetics
dc.typeArticle
dc.contributor.departmentDUKE-NUS GRADUATE MEDICAL SCHOOL S'PORE
dc.description.doi10.1016/j.antiviral.2012.07.008
dc.description.sourcetitleAntiviral Research
dc.description.volume96
dc.description.issue1
dc.description.page32-35
dc.description.codenARSRD
dc.identifier.isiut000310668000004
Appears in Collections:Staff Publications

Show simple item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

74
checked on Jun 9, 2021

WEB OF SCIENCETM
Citations

75
checked on Jun 9, 2021

Page view(s)

90
checked on Jun 7, 2021

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.